Name | FAUC-365 |
Description | FAUC-365 is a D3 dopamine receptor agonist. |
In vitro | As a dichloro derivative, FAUC-365 revealed D3 affinities that were comparable to its methoxy-substituted analogs, however, the selectivities of FAUC-365 against 5HT-1A, 5-HT2, and R1 were substantially higher, which was demonstrated by the extraordinary selectivity ratios of 17600, 7200, 5200, and 680 over D1, D2long, D2short, and D4, respectively, were determined for FAUC-365 with Ki of 0.50 nM. In addition, the benzothiophene analog FAUC 346 and its oxa analog showed partial agonist character with EC50 values at 0.36 and 1.5 nM, respectively [1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : insoluble DMSO : 50 mg/mL (108.12 mM) EtOH : insoluble
|
Keywords | inhibit | Parkinson's disease | Dopamine Receptor | FAUC365 | D3 receptor | Dopamine | Inhibitor | schizophrenia | SPET | FAUC 365 | Radioligand | FAUC-365 |
Inhibitors Related | Olanzapine | CLOZAPINE N-OXIDE | Mirtazapine | Promazine hydrochloride | Octopamine hydrochloride | Octodrine | Citicoline | Phenothiazine | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride | Fluphenazine dihydrochloride |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |